AbCellera Biologics ABCL
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of AbCellera Biologics (ABCL)
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Key Insights
Critical company metrics and information
Latest Closing Price
$2.33Market Cap
$694.31 MillionPrice-Earnings Ratio
-3.82Total Outstanding Shares
297.99 Million SharesTotal Employees
596Dividend
No dividendIPO Date
December 11, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
2215 yukon street, Vancouver, A1, V5Y 0A1Homepage
https://www.abcellera.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $61.38 Million |
| Net Cash Flow | $-45.78 Million |
| Net Cash Flow From Financing Activities | $12.39 Million |
| Net Cash Flow From Financing Activities, Continuing | $12.39 Million |
| Net Cash Flow From Operating Activities, Continuing | $-120.17 Million |
| Net Cash Flow From Operating Activities | $-120.17 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $341.03 Million |
| Other Operating Expenses | $141.98 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Benefits Costs and Expenses | $235.13 Million |
| Research and Development | $169.81 Million |
| Income Tax Expense/Benefit | $-26.37 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-175.22 Million |
| Comprehensive Income/Loss Attributable To Parent | $-175.57 Million |
| Other Comprehensive Income/Loss | $-50.53 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Cash | $643.14 Million |
| Intangible Assets | $52.58 Million |
| Other Current Assets | $99.74 Million |
| Current Assets | $742.88 Million |
| Equity | $1.08 Billion |
| Other Non-current Assets | $597.37 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ABCL from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.